Therefore, suppression of in situ estrogen formation, particularly in the breast of postmenopausal women by aromatase inhibitors (AIs), is considered as a useful way to prevent and treat breast cancer in these patients. The gene discussed is CYP19A1; the disease is breast carcinoma.